In Lyme-endemic areas: what Pfizer–Valneva’s VALOR results mean for vaccine decisions
Pfizer and Valneva’s Phase 3 VALOR trial of the Lyme vaccine candidate PF-07307405 produced a mixed but important result: the…
Pfizer and Valneva’s Phase 3 VALOR trial of the Lyme vaccine candidate PF-07307405 produced a mixed but important result: the…